Sign Out
Concomitant use of rosuvastatin and an antacid containing aluminium hydroxide and magnesium hydroxide decreased rosuvastatin peak plasma concentration and area under the plasma concentration-time curve (AUC) by 50%. The antacid should be administered at least 2 hours after rosuvastatin.
Concomitant use of rosuvastatin and itraconazole increased rosuvastatin peak plasma concentration and AUC by 1.4-fold.
Concomitant use of rosuvastatin and colchicine increases the risk of myopathy, including rhabdomyolysis.
Concomitant use of rosuvastatin and cyclosporine increases plasma rosuvastatin concentration, which may increase the risk of myopathy.
Concomitant use of rosuvastatin and digoxin increased both peak plasma concentration and AUC of digoxin by 4%.
Concomitant use of rosuvastatin and erythromycin decreased rosuvastatin peak plasma concentration and AUC by 30 and 20%, respectively.
Coadministration of rosuvastatin with gemfibrozil increases the risk of myopathy and/or rhabdomyolysis.
Coadministration of rosuvastatin with oral contraceptives increased the AUC for norgestrel and estradiol by approximately 34% and 26%, respectively.
Continue with Google